, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L,
Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and
peppermint oil in the treatment of irritable bowel syndrome:
systematic review and meta-analysis.
BMJ
2008;
337
: a2313
[PMID: 19008265 DOI: 10.1136/bmj.a2313]
253
Drossman DA
, Chey WD, Johanson JF, Fass R, Scott C, Panas
R, Ueno R. Clinical trial: lubiprostone in patients with
constipation-associated irritable bowel syndrome--results of two
randomized, placebo-controlled studies.
Aliment Pharmacol Ther
2009;
29
: 329-341 [PMID: 19006537 DOI: 10.1111/j.1365-
2036.2008.03881.x]
254
Ford AC
, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE,
Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in
irritable bowel syndrome: systematic review and meta-analysis.
Am J Gastroenterol
2009;
104
: 1831-143; quiz 1844 [PMID:
19471254 DOI: 10.1038/ajg.2009.223]
255
Andresen V
, Montori VM, Keller J, West CP, Layer P, Camilleri
M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists
on symptom relief and constipation in nonconstipated irritable
bowel syndrome: a systematic review and meta-analysis of
randomized controlled trials.
Clin Gastroenterol Hepatol
2008;
6
:
545-555 [PMID: 18242143 DOI: 10.1016/j.cgh.2007.12.015]
256
Tack J
, van Outryve M, Beyens G, Kerstens R, Vandeplassche
L. Prucalopride (Resolor) in the treatment of severe chronic
constipation in patients dissatisfied with laxatives.
Gut
2009;
58
:
357-365 [PMID: 18987031 DOI: 10.1136/gut.2008.162404]
257
Tack J
, Talley NJ. Functional dyspepsia--symptoms, definitions
and validity of the Rome III criteria.
Nat Rev Gastroenterol
Hepatol
2013;
10
:
134-141
[PMID:
23399526
DOI:
10.1038/nrgastro.2013.14]
258
Quigley EM
, Vandeplassche L, Kerstens R, Ausma J. Clinical
trial: the efficacy, impact on quality of life, and safety and
tolerability of prucalopride in severe chronic constipation--a 12-
week, randomized, double-blind, placebo-controlled study.
Aliment Pharmacol Ther
2009;
29
: 315-328 [PMID: 19035970
DOI: 10.1111/j.1365-2036.2008.03884.x]
259
Jones BW
, Moore DJ, Robinson SM, Song F. A systematic
review of tegaserod for the treatment of irritable bowel
syndrome.
J Clin Pharm Ther
2002;
27
: 343-352 [PMID:
12383135]
260
Rao S
, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, Shi K,
MacDougall JE, Shao JZ, Eng P, Fox SM, Schneier HA, Kurtz CB,
Johnston JM. A 12-week, randomized, controlled trial with a 4-
week randomized withdrawal period to evaluate the efficacy and
safety of linaclotide in irritable bowel syndrome with constipation.
Am J Gastroenterol
2012;
107
: 1714-124; quiz p.1725 [PMID:
22986440]
261
Chey WD
, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG,
MacDougall JE, Jia XD, Shao JZ, Fitch DA, Baird MJ, Schneier HA,
Johnston JM. Linaclotide for irritable bowel syndrome with
constipation: a 26-week, randomized, double-blind, placebo-
controlled trial to evaluate efficacy and safety.
Am J Gastroenterol
2012;
107
: 1702-1712 [PMID: 22986437]
262
Efskind PS
, Bernklev T, Vatn MH. A double-blind placebo-
controlled trial with loperamide in irritable bowel syndrome.
Scand J Gastroenterol
1996;
31
: 463-468 [PMID: 8734343]
263
Lavö B
, Stenstam M, Nielsen AL. Loperamide in treatment of
irritable bowel syndrome--a double-blind placebo controlled
study.
Scand J Gastroenterol Suppl
1987;
130
: 77-80 [PMID:
3306903]
264
Zighelboim J
, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister
AR. Visceral perception in irritable bowel syndrome. Rectal and
gastric responses to distension and serotonin type 3 antagonism.
